Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity HCT for Severe Sickle Cell Disease
NCT04362293Phase 2Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Apr 2020
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial in sickle cell disease (SCD) (2 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Donor T-cell chimerism at 1 year. Started Apr 2020; status: active, not recruiting.
02
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04362293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04362293.